Monsanto is to invest several hundred million dollars in Europe over a decade to expand their conventional seed production and breeding. By doing so, Monsanto will retain all pending genetically modified (GM) applications except for MON 810.
In a statement, the company said: "Biotech crops are highly successful in the rest of the world. In order to fully support both of these success stories, we will no longer be pursuing approvals for cultivation of new biotech crops in Europe.
"Instead, we will focus on enabling imports of biotech crops into the EU and the growth of our current business there."
